1. Medicines
  2. Oncology
  3. TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)

Tafinlar + Mekinist

Tafinlar® + Mekinist®

____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
Rate this content: 
No votes yet

Unresectable or metastatic melanoma - Patient guide

Stage III melanoma - Patient guide

November 2024 | IE11251839
Oncology
Medicines
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.